KNSA Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference

HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 9:40 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at . A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit .

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!™

Kiniksa Investor and Media Contact

Rachel Frank

(339) 970-9437



EN
01/06/2021

Underlying

KNSAKiniksa Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kiniksa Pharmaceuticals

 PRESS RELEASE
Free
KNSA Kiniksa Pharmac...

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results a...

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $930 - $945 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end –– Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (Kini...

9h / 11m 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
KNSA KINIKSA PHARMACEUTICALS
9h / 38m 9h / 38m 1 EN
Wedbush Research
  • Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
CNK CINEMARK HOLDINGS INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
AJX GREAT AJAX
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
ROKU ROKU INC. CLASS A
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
STOK STOKE THERAPEUTICS
STTK SHATTUCK LABS
NUVB NUVATION BIO INC (A)
STX SEAGATE TECHNOLOGY HLDGS PLC
ELYM ELIEM THERAPEUTICS INC
TTD THE TRADE DESK
EWTX INC.
ARTV EDGEWISE THERAPEUTICS INC
SYRE ARTIVA BIOTHERAPEUTICS INC
DBD SPYRE THERAPEUTICS INC.
ORKA DIEBOLD NIXDORF INCORPORATED
SNDK ORUKA THERAPEUTICS INC
TRAX V SANDISK CORP
FIRST TRACKS BIOTHERAPEUTICS INC
04/27/26 April 27, 2026 1 EN
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
XNCR XENCOR INC.
SRPT SAREPTA THERAPEUTICS INC.
NVCR NOVOCURE LTD.
ARDX ARDELYX INC
WVE WAVE LIFE SCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
STTK SHATTUCK LABS
NUVB NUVATION BIO INC (A)
ELYM ELIEM THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SYRE SPYRE THERAPEUTICS INC.
ORKA ORUKA THERAPEUTICS INC
TRAX V FIRST TRACKS BIOTHERAPEUTICS INC
04/24/26 April 24, 2026 1 EN
 PRESS RELEASE
Free
KNSA Kiniksa Pharmac...

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results...

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at . Individuals interested in participating in the call via telephone may register . Upon registration, all telephone participants will recei...

April 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch